App an effective tool to record sun exposure

by Queensland University of TechnologyCredit: Queensland University of TechnologyA smartphone app is an accessible tool that reliably measures the amount of exposure to the sun's skin-damagin

Oncology March 30,2024

App an effective tool to record sun exposure

by Queensland University of TechnologyCredit: Queensland University of TechnologyA smartphone app is an accessible tool that reliably measures the amount of exposure to the sun's skin-damagin

Oncology March 30,2024

BRCA1/2 genetic testing recommendations still leave issues unresolved

by Perelman School of Medicine at the University of PennsylvaniaCredit: CC0 Public DomainThe U.S. Preventive Services Task Force (USPSTF) has released a new Recommendation Statement forBRCA

Oncology March 30,2024

BRCA1/2 genetic testing recommendations still leave issues unresolved

by Perelman School of Medicine at the University of PennsylvaniaCredit: CC0 Public DomainThe U.S. Preventive Services Task Force (USPSTF) has released a new Recommendation Statement forBRCA

Oncology March 30,2024

ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastin

Oncology March 30,2024

ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastin

Oncology March 30,2024

ASCO: undertreatment seen for women with head and neck cancer

(HealthDay)—Females with head and neck cancer (HNC) are less likely to receive intensive chemotherapy and radiation, and have an increased relative risk for death from HNC versus other causes, accordi

Oncology March 30,2024

ASCO: undertreatment seen for women with head and neck cancer

(HealthDay)—Females with head and neck cancer (HNC) are less likely to receive intensive chemotherapy and radiation, and have an increased relative risk for death from HNC versus other causes, accordi

Oncology March 30,2024

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

(HealthDay)—For frail and elderly patients with advanced gastroesophageal cancer (aGOAC), low-dose chemotherapy is noninferior to high-dose chemotherapy for progression-free survival, according to a s

Oncology March 30,2024

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

(HealthDay)—For frail and elderly patients with advanced gastroesophageal cancer (aGOAC), low-dose chemotherapy is noninferior to high-dose chemotherapy for progression-free survival, according to a s

Oncology March 30,2024

An antenna for detecting breast cancer

by David Bradley,InderscienceCredit: CC0 Public DomainBreast cancer is a common illness around the world. It is the most common invasive of cancers in women and affects around one in eight and r

Oncology March 30,2024

An antenna for detecting breast cancer

by David Bradley,InderscienceCredit: CC0 Public DomainBreast cancer is a common illness around the world. It is the most common invasive of cancers in women and affects around one in eight and r

Oncology March 30,2024

ASCT may offer alternative for therapy for high-risk follicular lymphoma

(HealthDay)—Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, accordin

Oncology March 30,2024

ASCT may offer alternative for therapy for high-risk follicular lymphoma

(HealthDay)—Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, accordin

Oncology March 30,2024

ASH: A+CHP bests CHOP for peripheral T-cell lymphoma

(HealthDay)—For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincris

Oncology March 30,2024

ASH: A+CHP bests CHOP for peripheral T-cell lymphoma

(HealthDay)—For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincris

Oncology March 30,2024

ASCO: Low-fat dietary pattern cuts breast cancer deaths

(HealthDay)—A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up, according to

Oncology March 30,2024

ASCO: Low-fat dietary pattern cuts breast cancer deaths

(HealthDay)—A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up, according to

Oncology March 30,2024

BRAF inhibitor shows promising results in pediatric patients with low-grade glioma

by American Association for Cancer ResearchGlioma of the left parietal lobe. CT scan with contrast enhancement. Credit: Mikhail Kalinin/CC BY-SA 3.0Dabrafenib (Tafinlar), a BRAF inhibitor approve

Oncology March 30,2024

BRAF inhibitor shows promising results in pediatric patients with low-grade glioma

by American Association for Cancer ResearchGlioma of the left parietal lobe. CT scan with contrast enhancement. Credit: Mikhail Kalinin/CC BY-SA 3.0Dabrafenib (Tafinlar), a BRAF inhibitor approve

Oncology March 30,2024